C. L. Ventola

P & T : a peer-reviewed journal for formulary management · 2014–2017

A researcher in the Science corpus: 5 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom C. L. Ventola trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Sőnke Svenson
  2. D. Tomalia

Who trusts C. L. Ventola overall

  1. Aaron J. Young
  2. Manas Gaur
  3. Daniel P. Ferris
  4. Giuseppe Aceto
  5. O. Schutter
  6. Ibrahim T. Ozbolat
  7. Ligang Song
  8. Amanuel Alambo
  9. Valerio Persico
  10. S. Kraemer

Papers from C. L. Ventola's perspective

Ordered by how strongly the researchers C. L. Ventola trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Dendrimers in biomedical applications--reflections on the field. (Advanced Drug Delivery Reviews)
  2. How smartphones are changing the face of mobile and participatory healthcare: an overview, with example from eCAALYX (BioMedical Engineering OnLine)
  3. Smartphone App Use Among Medical Providers in ACGME Training Programs (Journal of medical systems)
  4. Human microvasculature fabrication using thermal inkjet printing technology. (Biomaterials)
  5. Cell and organ printing 1: protein and cell printers. (Anatomical Record Part A-discoveries in Molecular Cellular and Evolutionary Biology)
  6. Social Uses of Personal Health Information Within PatientsLikeMe, an Online Patient Community: What Can Happen When Patients Have Access to One Another’s Data (Journal of Medical Internet Research)
  7. Medicine 2.0: Social Networking, Collaboration, Participation, Apomediation, and Openness (Journal of Medical Internet Research)
  8. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. (The Lancet Oncology)
  9. Phase II trial of gefitinib in recurrent glioblastoma. (Journal of Clinical Oncology)
  10. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. (The Lancet Oncology)

Their papers